| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1997;96:3867-3872.)
© 1997 American Heart Association, Inc.
Articles |
From The Cleveland (Ohio) Clinic Foundation.
Correspondence to Stephen G. Ellis, MD, The Cleveland Clinic Foundation, 9500 Euclid Ave, F-25, Cleveland, OH 44195. E-mail elliss{at}cesmtp.ccf.org
| Abstract |
|---|
|
|
|---|
Methods and Results To assess the results of
percutaneous ULMT treatment from a wide variety of
experienced interventional centers, we requested data on consecutive
patients treated after January 1, 1994, from 25 centers. One hundred
seven patients were identified who were treated either electively
(n=91) or for acute myocardial infarction (n=16). Of patients treated
electively, 25% were considered inoperable, and 27% were considered
high risk for bypass surgery. Primary treatment included stents (50%),
directional atherectomy (24%), and balloon angioplasty (20%).
Follow-up was 98.8% complete at 15±8 months. Results varied
considerably, depending on presentation and treatment. For
patients with acute myocardial infarction, technical success was
achieved in 75%, and survival to hospital discharge was 31%. For
elective patients, technical success was achieved in 98.9%, and
in-hospital survival was strongly correlated with left
ventricular ejection fraction (P=.003).
Longer-term event (death, infarction, or bypass surgery) -free survival
was correlated with ejection fraction (P<.001) and was
inversely related to presentation with progressive or rest
angina (P<.001). Surgical candidates with ejection
fractions
40% had an in-hospital survival of 98% and a 9-month
event-free survival of 86±5%, whereas patients with ejection
fractions <40% had 67% and 22±12% in-hospital and 9-month
event-free survivals, respectively. Nine hospital survivors (10.6%)
experienced cardiac death within 6 months of hospital discharge.
Conclusions While results for selected patients appear promising, until early posthospital discharge cardiac death can be better understood and minimized, percutaneous revascularization of ULMT stenosis should not be considered an alternative to bypass surgery for most patients. When percutaneous revascularization of ULMT is required, directional atherectomy and stenting appear to be the preferred techniques, and follow-up angiography 6 to 8 weeks after treatment is probably advisable.
Key Words: angioplasty bypass coronary disease arteries stents
| Introduction |
|---|
|
|
|---|
Whether such a percutaneous approach can be considered an acceptable alternative to CABG remains unknown. To evaluate this, a multicenter registry was developed to study the initial and long-term outcome of the various subgroups of patients who might be considered for percutaneous treatment of unprotected LMT stenoses.
| Methods |
|---|
|
|
|---|
Data Collection and Statistical Analysis
Data collected on dedicated case report forms and procedural
cineangiograms were forwarded to the coordinating center
for data entry, cross-checking, and analysis. Angiographic
analysis was performed by core laboratory physicians who were
blinded to clinical outcome using electronic calipers, catheter
calibration, and standard definitions.12
The following data elements were obtained.
Baseline Angiographic Data
This information included left ventricular ejection
fraction (LVEF), lesion length (shoulder to shoulder), location of
stenosis (
30% narrowingostial, proximal, or distal),
"normal" reference dimension (in millimeters), number of diseased
vessels, occluded right coronary artery, and pretreatment
percent stenosis.
Baseline Clinical Data
Data were collected on age, aortic insufficiency, chronic
obstructive pulmonary disease, creatinine
2 mg%,
current smoker, diabetes, sex, hyperlipidemia,
hypertension, jeopardy score,13 malignancy, mitral
insufficiency, peripheral vascular disease
(symptomatic), presentation (acute myocardial
infarction from LMT stenosis or occlusion, cardiogenic shock,
stable angina, or unstable angina), prior bypass surgery (and years
since that operation), and recent infarction (within 2 weeks).
Stated Primary Reason for Percutaneous Therapy
The stated reasons included high risk for CABG, limited life
expectancy, patient preference in the absence of high surgical risk
(common practice at several Asian centers), and refusal by surgeons for
CABG.
Treatment
Data were collected on the use of abciximab, aspirin,
ß-blockers, blood product transfusion, calcium channel
blockers, cardiopulmonary support (as an adjunct to
revascularization), intra-aortic balloon pump,
intubation, nitrates, other coronary sites treated,
peripheral vascular repair, procedure date,
percutaneous therapy (pretreatment, primary and bailout
[separately]: balloon angioplasty, directional atherectomy,
rotational atherectomy, or stent), specific technical modifications
(eg, use of intravascular ultrasound or a perfusion balloon for
angioplasty), ticlopidine, vasopressors during the
revascularization, and warfarin.
In-Hospital Outcome
This information included bypass surgery (and elective or
emergency), death (and cause of death-cardiac or noncardiac),
dialysis, length of stay, maximum posttreatment creatine kinase,
myocardial infarction (and Q-wave or nonQ-wave infarction), and
posttreatment percent stenosis.
Follow-up
We collected follow-up information on CABG, death (and cause of
death), myocardial infarction, repeated percutaneous
intervention, and restenosis.
Questions and Hypothesis
We prospectively sought to determine procedural, in-hospital,
and long-term outcome in the entire cohort and in patients
presenting or treated with acute myocardial infarction, directional
atherectomy as primary therapy, differing stenosis location,
LVEF
40% or <40%, other devices as primary therapy, stable angina,
stents as primary therapy, surgically accepted, surgically high risk,
surgically refused, unstable angina.
Data are presented as percent incidence, mean±SD, or median
and interquartile range as appropriate. Between-group comparisons were
performed by use of Student's t and
2 tests
and by Cox and logistic regression analyses. Statistical
significance was assumed at a value of P<.05.
| Results |
|---|
|
|
|---|
|
|
Treatment and In-Hospital Outcomes
The primary treatments used were the Palmaz-Schatz stent (n=45),
directional atherectomy (n=27), balloon angioplasty (n=21), Rotablator
(n=5), the Gianturco-Roubin I stent (n=2), the Palmaz "Biliary"
stent (n=2), the ACS stent (n=1), the Cordis stent (n=1), the
Gianturco-Roubin II stent (n=1), and the NIR stent (n=1). In 11
instances of stenting, preliminary debulking was performed (Rotablator
[n=10] or directional atherectomy [n=1]).
Hemodynamic support devices were used in 68% of the
patients (intra-aortic balloon pump in 62 patients,
cardiopulmonary support in 11). All patients were pretreated
with aspirin, and 26 were also treated with ticlopidine. Only 2
received abciximab.
Choice of primary therapy appeared to depend on clinical
presentation and, to a certain extent, clinical site (see
Table 3
). Balloon angioplasty was used
more often in patients with acute infarction (adjusted odds ratio,
11.5; multivariate P=.002). Directional
atherectomy was used less commonly in nonsurgical candidates (adjusted
odds ratio, 0.07; P=.014) and slightly more commonly in
patients with distal LMT involvement (adjusted odds ratio, 2.9;
P=.08). Stent usage was not related to any variable
studied. Stenting of distal LMT lesions almost always was accomplished
with a single stent spanning the distal LMT and the proximal portion of
the larger of the anterior descending or circumflex arteries. All
stents were implanted at pressures
12 atm. Intravascular ultrasound
use was recorded in 42.9% of elective cases.
|
Considering all patients, technical success (final stenosis
<50% diameter stenosis and Thrombosis in Myocardial
Infarction grade 3 flow) was achieved in all but 4 patients (96.2%).
Stenoses were reduced from 70±16% to 15±19% (balloon
angioplasty, 37±19%; directional atherectomy, 12±13%; and stents,
7±14%). Eleven of 16 patients (69%) presenting with acute
infarction died in hospital. Excluding these patients, in-hospital
outcomes were as follows: cardiac death, 11.0%; noncardiac death,
1.1%; Q-wave infarction, 4.5%, nonQ-wave infarction, 10.1%; bypass
surgery, 1.1%; peripheral vascular surgery, 4.4%; blood
product transfusion, 36.3%; and median length of stay, 8 days.
Four deaths occurred in the catheterization laboratory,
three of which occurred in patients with LVEF <40%. Two in-hospital
deaths were not believed to be cardiovascular: One was
due to sepsis and the other to pneumonia. Outcomes varied dramatically,
depending on several patient characteristics (Tables 4
and 5
).
|
|
PostHospital Discharge Outcome
Mean follow-up is currently 15±9 months. One patient was lost to
follow-up after surviving 3 months. Excluding patients presenting
with infarction, 1-, 6-, and 12-month survival and event (death,
infarction, bypass surgery) -free survivals were 88.8±3.5%,
72.6±4.8%, and 70.9±5.0%, and 87.5±3.5%, 68.1±5.1%, and
68.1±5.1%, respectively. Three deaths were directly attributable to
cancer. These results varied considerably by patient subgroup (Tables 6
and 7
and
Figs 1
and 2
).
|
|
|
|
Importantly, nine hospital survivors (10.6%) died of cardiac or
presumed cardiac cause within 6 months. Most had presented with
unstable angina and had been treated with stents. All patients except
one were discharged on aspirin and ticlopidine, and one was also taking
warfarin at the time of death (Table 8
).
|
Overall event-free survival for patients not treated for initial
myocardial infarction was significantly correlated with low ejection
fraction, presentation with progressive or rest angina,
and, to a lesser degree, use of treatments other than directional
atherectomy (Tables 6
and 7
).
Of patients eligible for >4-month angiography, 70% had known studies,
of whom 22.0% had restenosis (stenosis
50%). In
this small cohort, the only variable related to risk of
restenosis was ostial LMT location (odds ratio, 4.67;
P=.07).
| Discussion |
|---|
|
|
|---|
Early reports of conventional percutaneous transluminal coronary angioplasty in this setting did little to dissuade clinicians from this conclusion. The report of O'Keefe et al2 from the Mid-America Heart Institute in 1989 was both representative and sobering, reporting a 55% 6-month mortality in 26 such patients.
The techniques of stenting and directional and rotational atherectomy have matured greatly in nearly 10 years of clinical experience.15 Since the early report of Macaya et al,4 an increasing number of small-scale reports of generally successful outcomes with unprotected LMT stenting or atherectomy have been reported.511 Several centers in Asia now offer these therapies as alternatives to CABG in selected patients.
This report, although still modest in scope, is the first to study >40
patients and to evaluate results in more than a few categories of
patients. Short- and intermediate-term results varied greatly,
depending on a number of factors. Excluding presentation
with acute myocardial infarction, LVEF was the most important risk
factor for in-hospital death. In elective cases, when LVEF was
40%,
mortality was only 1.7% (n=59), whereas when LVEF was <30%,
mortality was 31.8% (n=22), Three of the seven deaths in the latter
group occurred in the catheterization laboratory,
attesting to the intolerance of the impaired left ventricle to even
short periods of near-global ischemia. Acceptable event-free
survival over time was also related to high LVEF but also to the
absence of severe unstable angina at baseline and possibly to the use
of directional atherectomy as the treatment modality (Table 6
). These
data should be contrasted with those from patients receiving
thecontemporary therapy of "protected" LMT
stenosesthose with patent bypass grafts to the anterior
descending or circumflex territoriesin whom survival is generally
excellent.16
A disturbingly high incidence of cardiac or presumed cardiac death occurred during the first 6 months after treatment. This occurred primarily in patients with unstable angina, several of whom also had depressed left ventricular function, who were treated with stents, despite the use of aspirin, ticlopidine, and high-pressure inflations. Stent thrombosis, worsening heart failure, or arrhythmias without restenoses are plausible explanations for this finding. It is also possible that severe restenosis may precipitate rapidly worsening heart failure or electrical instability. It may be prudent to bring the patient back for angiographic restudy 6 to 8 weeks after treatment to attempt to detect early aggressive restenosis, although the benefit of such a course of action is, of course, yet unproven.
With limited data from selected hospital sites, it is difficult to define the role of percutaneous intervention for patients with unprotected LMT stenoses. Less experienced sites might not be able to replicate these results. The impressions from subset analyses of this experience need to be studied further, because the likelihood of some type I statistical error is fairly high. If the early postdischarge events could be minimized, a strategy of LMT directional atherectomy or stenting for patients with stable or new-onset angina and well-preserved left ventricular dysfunction, when practiced in highly experienced centers, would not appear to be totally unreasonable. Before such a practice could to be accepted, randomized controlled trials comparing long-term outcome against that with bypass surgery would need to be completed. Percutaneous intervention for inoperable patients with LMT stenoses may be reasonable for those individuals with intractable symptoms. All groups of patients might be expected to have improved outcomes with adjunctive use of abciximab or related drugs, which have been demonstrated to decrease the risk of infarction with directional atherectomy17 and emergency stenting18 and are under study in the setting of elective stenting.
| Acknowledgments |
|---|
Received May 22, 1997; revision received August 27, 1997; accepted August 28, 1997.
| References |
|---|
|
|
|---|
2. O'Keefe JH, Hartzler GO, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Ligon RW. Left main coronary angioplasty: early and late results of 127 acute and elective procedures. Am J Cardiol. 1989;64:144147.[Medline] [Order article via Infotrieve]
3. ACC/AHA Task Force. Guidelines and indications for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol. 1991;17:543589.[Medline] [Order article via Infotrieve]
4. Macaya C, Alfonso F, Iñiguez A, Goicolea J, Hernandez R, Zarco P. Stenting for elastic recoil during coronary angioplasty of the left main coronary artery. Am J Cardiol. 1992;70:105107.[Medline] [Order article via Infotrieve]
5. Chaix AF, Barragan P, Silvestri M, Comet B, Bouvier JL, Chaix L, Latour F, Camilleri JF, Garcia P. Rotablator and endoprosthesis on the left main coronary trunk. Arch Mal Couer Vaiss. 1995;88:9597.[Medline] [Order article via Infotrieve]
6. Rozenman Y, Lotan C, Weiss AT, Gotsman MS. Emergency rotational ablation of a calcified left main coronary artery stenosis in a patient with ischemic induced cardiogenic shock. Cath Cardiovasc Diagn. 1995;36:6366.[Medline] [Order article via Infotrieve]
7. Fajadet J, Brunel P, Jordan C, Cassagneau B, Marco J. Stenting of unprotected left main coronary artery stenosis without Coumadin. J Am Coll Cardiol. 1996;27:277A. Abstract
8. Itoh A, Colombo A, Hall P, Maiello L, Di Mario C, Blengino S, Ferraro M, Martini G, Di Francesco L, Finci L. Stenting in protected and unprotected left main coronary artery: immediate and follow-up results. J Am Coll Cardiol. 1996;27:277A. Abstract.
9. Tamura T Nobuyoshi M, Nosaka H, Kimura T, Yokoi H, Hamasaki N, Nakagawa Y, Yokoi Y, Nakano Y, Hayashi F. Palmaz-Schatz stenting in unprotected and protected left main coronary artery: immediate and follow-up results. Circulation. 1996;94(suppl I):I-671. Abstract.
10. Barragan P, Silvestri M, Simeoni JB, Sainsous J, Roquebert PO, Bayet G, Comet B, Bouvier JL. Stenting in unprotected left main coronary artery: immediate and follow-up results. Circulation. 1996;94(suppl I):I-672. Abstract.
11. Tanaka S, Ueda K, Yung-Sheng H, Ono S, Kosuga K, Matsui S, Nakamura T, Minami M, Motohara S, Uehata H. Initial and long-term results of directional coronary atherectomy of unprotected left main coronary artery. Circulation. 1996;94(suppl I):I-672. Abstract.
12. Alderman EL, Stadius M. The angiographic definitions of the Bypass Angioplasty Revascularization Investigation. Coron Art Dis. 1992;3:11891207.
13. Ellis SG, Myler RK, King SB, Douglas JS, Topol EJ, Shaw RE, Stertzer SH, Roubin GS, Murphy MC. Causes and correlates of cardiac death after unsupported coronary angioplasty: implications for the use of advanced support techniques. Am J Cardiol. 1991;68:14471451.[Medline] [Order article via Infotrieve]
14. Ellis SG, Hill CM, Lytle BW. The spectrum of surgical risk for left main coronary stenoses: benchmark for potentially competing percutaneous therapies. In press.
15. Williams DO. Catheterization interventions for the treatment of coronary artery disease: techniques, results, and patient selection. In: Smith TW, ed. Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease. Philadelphia, Pa: WB Saunders Co; 1996:5765.
16. Lopez JJ, Ho KKL, Stoler RC, Caputo RP, Carrozza JP, Kuntz RE, Baim DS, Cohen DJ. Percutaneous treatment of protected and unprotected left main coronary stenoses with new devices: immediate angiographic results and intermediate-term follow-up. J Am Coll Cardiol. 1997;29:345352.[Abstract]
17. Lefkovits J, Blankenship JC, Anderson KM, Stoner GL, Talley JD, Worley SJ, Weisman HF, Califf RM, Topol EJ, for the EPIC Investigators. Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. J Am Coll Cardiol. 1996;28:849855.[Abstract]
18. Zidar JP, Kruse KR, Thel MC, Kereiakes D, Muhlestein JB, Davidson CJ, Teirstein PS, Tenaglia A, Yakubov SJ, Popma JJ, Tanguay J-F, Kitt MM, Lorenz T, Tcheng JE, Lincoff AM, Califf RM, Topol EJ, for the IMPACT II Investigators. Integrelin for emergency coronary artery stenting. J Am Coll Cardiol. 1996;27:138A. Abstract.
This article has been cited by other articles:
![]() |
P. G. Malvindi, J. Dunning, and N. Vitale For which patients with left main stem disease is percutaneous intervention rather than coronary artery bypass grafting the better option? Interactive CardioVascular and Thoracic Surgery, April 1, 2008; 7(2): 306 - 314. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Brinker The left main facts: faced, spun, but alas too few. J. Am. Coll. Cardiol., March 4, 2008; 51(9): 893 - 898. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Erglis, I. Narbute, I. Kumsars, S. Jegere, I. Mintale, I. Zakke, U. Strazdins, and A. Saltups A Randomized Comparison of Paclitaxel-Eluting Stents Versus Bare-Metal Stents for Treatment of Unprotected Left Main Coronary Artery Stenosis J. Am. Coll. Cardiol., August 7, 2007; 50(6): 491 - 497. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Chieffo, N. Morici, F. Maisano, E. Bonizzoni, J. Cosgrave, M. Montorfano, F. Airoldi, M. Carlino, I. Michev, G. Melzi, et al. Percutaneous Treatment With Drug-Eluting Stent Implantation Versus Bypass Surgery for Unprotected Left Main Stenosis: A Single-Center Experience Circulation, May 30, 2006; 113(21): 2542 - 2547. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Valgimigli, P. Malagutti, G. A. Rodriguez-Granillo, H. M. Garcia-Garcia, J. Polad, K. Tsuchida, E. Regar, W. J. Van der Giessen, P. de Jaegere, P. De Feyter, et al. Distal Left Main Coronary Disease Is a Major Predictor of Outcome in Patients Undergoing Percutaneous Intervention in the Drug-Eluting Stent Era: An Integrated Clinical and Angiographic Analysis Based on the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) Registries J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1530 - 1537. [Abstract] [Full Text] [PDF] |
||||
![]() |
K D Dawkins, T Gershlick, M de Belder, A Chauhan, G Venn, P Schofield, D Smith, J Watkins, H H Gray, and Joint Working Group on Percutaneous Coronary Inter Percutaneous coronary intervention: recommendations for good practice and training Heart, December 1, 2005; 91(suppl_6): vi1 - vi27. [Abstract] [Full Text] [PDF] |
||||
![]() |
K Kosuga and H Tamai Left main stem coronary disease: the case for percutaneous coronary intervention in a high risk patient with complex disease Heart, June 1, 2005; 91(suppl_3): iii35 - iii38. [Full Text] [PDF] |
||||
![]() |
A. Chieffo, G. Stankovic, E. Bonizzoni, E. Tsagalou, I. Iakovou, M. Montorfano, F. Airoldi, I. Michev, M. G. Sangiorgi, M. Carlino, et al. Early and Mid-Term Results of Drug-Eluting Stent Implantation in Unprotected Left Main Circulation, February 15, 2005; 111(6): 791 - 795. [Abstract] [Full Text] [PDF] |
||||
![]() |
G Matos, L Steen, and F Leya Treatment of unprotected left main coronary artery stenosis with a drug eluting stent in a heart transplant patient with allograft vasculopathy Heart, February 1, 2005; 91(2): e11 - e11. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Carrozza Jr and F. W. Sellke A 69-Year-Old Woman With Left Main Coronary Artery Disease JAMA, November 24, 2004; 292(20): 2506 - 2514. [Full Text] [PDF] |
||||
![]() |
M. Singh, C. S. Rihal, F. Selzer, K. E. Kip, K. Detre, and D. R. Holmes Jr Validation of Mayo clinic risk adjustment model for in-hospital complications after percutaneous coronary interventions, using the National Heart, Lung, and Blood Institute dynamic registry J. Am. Coll. Cardiol., November 19, 2003; 42(10): 1722 - 1728. [Abstract] [Full Text] [PDF] |
||||
![]() |
B R G Brueren, J M P G Ernst, M J Suttorp, J M ten Berg, B J W M Rensing, E G Mast, E T Bal, A J Six, and H W M Plokker Long term follow up after elective percutaneous coronary intervention for unprotected non-bifurcational left main stenosis: is it time to change the guidelines? Heart, November 1, 2003; 89(11): 1336 - 1339. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Kelley, B. D. Klugherz, S. M. Hashemi, N. F. Meneveau, J. M. Johnston, W. H. Matthai Jr, V. S. Banka, H. C. Herrmann, J. W. Hirshfeld Jr, S. E. Kimmel, et al. One-year clinical outcomes of protected and unprotected left main coronary artery stenting Eur. Heart J., September 1, 2003; 24(17): 1554 - 1559. [Abstract] [Full Text] [PDF] |
||||
![]() |
H McArdle, M Bhandari, and J Kovac Emergency coronary stenting of unprotected critical left main coronary artery stenosis in acute myocardial infarction and cardiogenic shock Heart, September 1, 2003; 89(9): e24 - 24. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Empen, T. Bollmann, J. B. Dahm, T. Takagi, G. Stankovic, L. Finci, K. Toutouzas, N. Corvaja, R. Albiero, G. Sivieri, et al. Beneficial Outcome After Angioplasty of Unprotected Left Main Stenosis in Patients During Resuscitation * Response Circulation, April 8, 2003; 107 (13): e91 - e91. [Full Text] [PDF] |
||||
![]() |
M. Singh, R. J. Lennon, D. R. Holmes Jr, M. R. Bell, and C. S. Rihal Correlates of procedural complicationsand a simple integer risk scorefor percutaneous coronary intervention J. Am. Coll. Cardiol., August 7, 2002; 40(3): 387 - 393. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Takagi, G. Stankovic, L. Finci, K. Toutouzas, A. Chieffo, V. Spanos, F. Liistro, C. Briguori, N. Corvaja, R. Albero, et al. Results and Long-Term Predictors of Adverse Clinical Events After Elective Percutaneous Interventions on Unprotected Left Main Coronary Artery Circulation, August 6, 2002; 106(6): 698 - 702. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. L. Moura, G. Melissano, F. Maisano, E. M. Marone, E. Civilini, O. Alfieri, and R. Chiesa Combined Endovascular Treatment of a Descending Thoracic Aortic Aneurysm and Off-Pump Myocardial Revascularization: A Case Report Vascular and Endovascular Surgery, July 1, 2002; 36(4): 305 - 309. [Abstract] [PDF] |
||||
![]() |
F R. d'Allonnes, H Corbineau, H Le Breton, C Leclercq, A Leguerrier, and C Daubert Isolated left main coronary artery stenosis: long term follow up in 106 patients after surgery Heart, June 1, 2002; 87(6): 544 - 548. [Abstract] [Full Text] [PDF] |
||||
![]() |
A H Gershlick Intracoronary stenting: developments since the NICE report Heart, March 1, 2002; 87(3): 187 - 190. [Full Text] [PDF] |
||||
![]() |
M. Tariq, R. Carroll, I. Zabih, R.G. Stenberg, and K.M.A. Hussain Emergency Coronary Stenting for Complete Thrombotic Occlusion of an Unprotected Left Main Coronary Artery in Acute Myocardial Infarction Complicated by Cardiogenic Shock in an Octogenarian Patient: A Case Report Angiology, January 1, 2002; 53(1): 95 - 98. [Abstract] [PDF] |
||||
![]() |
W. A. Tan, H. Tamai, S.-J. Park, H.W. T. Plokker, M. Nobuyoshi, T. Suzuki, A. Colombo, C. Macaya, D. R. Holmes Jr, D. J. Cohen, et al. Long-Term Clinical Outcomes After Unprotected Left Main Trunk Percutaneous Revascularization in 279 Patients Circulation, October 2, 2001; 104(14): 1609 - 1614. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-J. Park, M.-K. Hong, C. W. Lee, J.-J. Kim, J.-K. Song, D.-H. Kang, S.-W. Park, and G. S. Mintz Elective stenting of unprotected left main coronary artery stenosis: Effect of debulking before stenting and intravascular ultrasound guidance J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1054 - 1060. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-K. Yip, C.-J. Wu, M.-C. Chen, H.-W. Chang, K. Y.-K. Hsieh, C.-L. Hang, and M. Fu Effect of Primary Angioplasty on Total or Subtotal Left Main Occlusion : Analysis of Incidence, Clinical Features, Outcomes, and Prognostic Determinants Chest, October 1, 2001; 120(4): 1212 - 1217. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Cohen, M. Doucet, D. E. Cutlip, K. K.L. Ho, J. J. Popma, and R. E. Kuntz Impact of Smoking on Clinical and Angiographic Restenosis After Percutaneous Coronary Intervention: Another Smoker's Paradox? Circulation, August 14, 2001; 104(7): 773 - 778. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.V Patil, E Nikolsky, M Boulos, E Grenadier, and R Beyar Multivessel coronary artery disease: current revascularization strategies Eur. Heart J., July 2, 2001; 22(14): 1183 - 1197. [PDF] |
||||
![]() |
A. Black Jr, R. Cortina, I. Bossi, R.e. Choussat, J. Fajadet, and J. Marco Unprotected left main coronary artery stenting: Correlates of midterm survival and impact of patient selection J. Am. Coll. Cardiol., March 1, 2001; 37(3): 832 - 838. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Al Suwaidi, P. B. Berger, and D. R. Holmes Jr Coronary Artery Stents JAMA, October 11, 2000; 284(14): 1828 - 1836. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Silvestri, P. Barragan, J. Sainsous, G. Bayet, J.-B. Simeoni, P.-O. Roquebert, G. Macaluso, J.-L. Bouvier, and B. Comet Unprotected left main coronary artery stenting: immediate and medium- term outcomes of 140 elective procedures J. Am. Coll. Cardiol., May 1, 2000; 35(6): 1543 - 1550. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Baim Is it time to offer elective percutaneous treatment of the unprotected left main coronary artery? J. Am. Coll. Cardiol., May 1, 2000; 35(6): 1551 - 1553. [Full Text] [PDF] |
||||
![]() |
C. E. Chambers, S. T Riebel, and M. Kozak Interventional Cardiology: Advances in Percutaneous Techniques for the Treatment of Cardiac Disease Seminars in Cardiothoracic and Vascular Anesthesia, July 1, 1999; 3(2): 109 - 125. [Abstract] [PDF] |
||||
![]() |
D. R. Holmes Jr., J. Hirshfeld Jr., D. Faxon, R. Vlietstra, A. Jacobs, S. B. King III, T. M. Bashore, N. D. Bridges, C. B. Higgins, L. F. Hiratzka, et al. ACC expert consensus document on coronary artery stents: Document of the American College of Cardiology J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1471 - 1482. [Full Text] [PDF] |
||||
![]() |
J. E. Molina, S. G. Ellis, H. Tamai, M. Nobuyoshi, K. Kosuga, A. Colombo, D. R. Holmes, C. Macaya, C. L. Grines, P. L. Whitlow, et al. Percutaneous Treatment of Left Main Coronary Stenosis • Response Circulation, October 13, 1998; 98(15): 1587 - 1590. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |